IFNB1抗体;IFNB1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12754(IFNB1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12754(IFNB1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

**Background of IFNB1 Antibodies**

IFNB1 (Interferon Beta-1) is a cytokine belonging to the type I interferon family, primarily produced by fibroblasts and immune cells in response to viral infections or inflammatory signals. It plays a critical role in innate immunity by binding to the IFN-α/β receptor (IFNAR), triggering JAK-STAT signaling pathways that induce antiviral, antiproliferative, and immunomodulatory responses. IFNB1 is clinically significant, with recombinant forms (e.g., IFN-β1a/b) used to treat multiple sclerosis.

Antibodies targeting IFNB1 are essential tools for studying its expression, regulation, and function. They enable the detection and quantification of IFNB1 in biological samples via techniques like Western blotting, ELISA, and immunohistochemistry. Additionally, neutralizing IFNB1 antibodies help dissect its role in immune responses or validate its involvement in disease models.

IFNB1 antibodies are typically raised in hosts like rabbits or mice, with formats ranging from polyclonal (broad epitope recognition) to monoclonal (high specificity). Validation includes testing in knockout cells or functional assays to ensure specificity and minimal cross-reactivity with related interferons (e.g., IFN-α). Commercial antibodies often cite applications in research on viral infections, autoimmune diseases, and cancer immunotherapy.

Researchers must select antibodies validated for their specific experimental needs, considering factors like species reactivity, post-translational modifications, and compatibility with downstream assays. Reliable suppliers include R&D Systems, Abcam, and Cell Signaling Technology. Proper controls are critical to avoid artifacts, given IFNB1's low endogenous levels in many physiological conditions.